Shots:
- The EC has approved Blenrep + BorDex & PomDex in MM pts with ≥1 prior therapy. Review ongoing in the US (PDUFA: Oct 23, 2025) & China (priority review for DREAMM-7)
- Approval was based on P-III (DREAMM-7 & DREAMM-8) trials assessing Blenrep + BorDex vs Darzalex + BorDex in 494 pts & Blenrep + PomDex (BPd) vs Velcade + PomDex in 302 pts, respectively
- DREAMM-7 showed improved PFS (1EP; mPFS: 36.6 vs 13.4mos.), depicting a 42% reduction in death risk at 39.4 mFU & 3yr. OS rate (2EP) of 74% vs 60% (mOS: unreached for both arm), while DREAMM-8 showed unreached mPFS vs 12.7mos. at mFU of 21.8mos.
Ref: GSK | Image: GSK | Press Release
Related News:- GSK Receives Health Canada’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
